CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma.

Koichiro KanamoriKentaro SuinaTakehito ShukuyaFumiyuki TakahashiTakuo HayashiKieko HaraTsuyoshi SaitoYoichiro MitsuishiShoko Sonobe ShimamuraWira WinardiKen TajimaRyo KoTomoyasu MimoriTetsuhiko AsaoMasayoshi ItohHideya KawajiYoshiyuki SueharaKazuya TakamochiKenji SuzukiKazuhisa Takahashi

Published in: Thoracic cancer (2023)

We identified CALML5 as a potential marker for differentiating thymic squamous cell carcinoma from type B3 thymoma. It is assumed that future clinical use of CALML5 may improve the diagnostic accuracy of differentiating between these two diseases.

Keyphrases

squamous cell carcinoma
contrast enhanced
lymph node metastasis
myasthenia gravis
locally advanced
current status
computed tomography